The minority owners of Fortis' SRL are once again trying to exit the Indian lab market, as GCC's Aster DM look set to enter with the launch of a new lab business.
"Health care services is a dirty enough business in Europe without us seeking more risk in Emerging Markets" was how a big private equity investor summed up his sentiment.
We examine a feast of data, the 2018 results, from Cerba, Synlab and Unilabs and contrast them with Sonic and Eurofins. What do they tell us about their performance across routine lab testing, acquisitions and diversification?
The French lab market contracted by 0.5% in 2018 as its public payor (CNAM) cut the national tariff to offset volume increases. HBI reveals how the country's largest groups faired.
Here are 10 more things that piqued our interest at HBI 2019, where sector stakeholders from payors to investors come together to grapple with the biggest and most interesting issues of the year.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
